Vernon H J, Lane A T, Weston W
Department of Dermatology, University of Rochester School of Medicine and Dentistry, New York.
J Am Acad Dermatol. 1991 Apr;24(4):603-7. doi: 10.1016/0190-9622(91)70092-g.
We conducted a 6-week randomized, blinded study that compared mometasone furoate 0.1% cream, applied once daily, and hydrocortisone 1.0% cream, applied twice daily, in 48 children with moderate to severe atopic dermatitis. Mometasone furoate, a moderate-potency steroid, produced significantly greater improvement than the low-potency hydrocortisone used twice daily. The difference in therapeutic response was particularly evident in patients with involvement of more than 25% of their body surface area. Morning plasma cortisol levels were assayed before treatment, after 1 week of therapy, and at the end of the clinical trial. Plasma cortisol levels were transiently suppressed in one child who was treated with hydrocortisone and in none of the children treated with mometasone.
我们进行了一项为期6周的随机、双盲研究，比较了每日一次外用0.1%糠酸莫米松乳膏与每日两次外用1.0%氢化可的松乳膏对48例中度至重度特应性皮炎患儿的疗效。中度效力的类固醇糠酸莫米松比每日两次使用的低效氢化可的松产生了显著更大的改善。治疗反应的差异在体表面积受累超过25%的患者中尤为明显。在治疗前、治疗1周后以及临床试验结束时检测早晨血浆皮质醇水平。接受氢化可的松治疗的一名儿童血浆皮质醇水平出现短暂抑制，而接受糠酸莫米松治疗的儿童中无一出现这种情况。
